Abbvie (ABBV) EPS (2013 - 2026)
Abbvie (ABBV) EPS from Mar 31, 2013 to Mar 31, 2026. The TTM Abbvie (ABBV) EPS is $1.76. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EPS
Quarterly EPS
Abbvie (ABBV) EPS CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -56.88% |
| 3 Years TTM | -29.11% |
| 5 Years TTM | -18.53% |
| 10 Years TTM | -8.24% |
| All Time TTM | -4.96% |
Annual EPS change of Abbvie (ABBV)
| Year | EPS | Change |
|---|---|---|
| 2026 | $0.39 | -83.56% |
| 2025 | $2.39 | -1.22% |
| 2024 | $2.42 | -12.08% |
| 2023 | $2.75 | -58.84% |
| 2022 | $6.68 | +2.49% |
| 2021 | $6.52 | +135.49% |
| 2020 | $2.77 | -47.97% |
| 2019 | $5.32 | +44.21% |
| 2018 | $3.69 | +10.94% |
| 2017 | $3.33 | -9.37% |
| 2016 | $3.67 | +15.94% |
| 2015 | $3.17 | +184.61% |
| 2014 | $1.11 | -57.19% |
| 2013 | $2.60 | -22.34% |
| 2012 | $3.34 | N/A |
Comparison Abbvie (ABBV) five years EPS CAGR with competitors
Abbvie (ABBV) five years EPS CAGR is -19.65%.
| Ticker | Name | five years EPS CAGR | Upside |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 98.59% | -601.71% |
| LLY | Lilly(Eli) & Company | 29.14% | -248.30% |
| NVO | Novo Nordisk | 24.26% | -223.44% |
| AZN | Astrazeneca plc | 17.09% | -186.99% |
| NVS | Novartis AG | 14.96% | -176.13% |
| JNJ | Johnson & Johnson | 11.59% | -158.97% |
| MRK | Merck & Co Inc | 5.37% | -127.34% |
| BMY | Bristol-Myers Squibb Company | 5.08% | -125.86% |
| GSK | GSK Plc | 4.65% | -123.67% |
| AMGN | AMGEN Inc | 3.49% | -117.78% |